New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 23, 2013
08:54 EDTBSTC, AUXLBioSpecifics says trial of CCH for canine lipoma did not meet primary endpoint
BioSpecifics Technologies (BSTC) announced top-line data from Chien-804, the placebo-controlled, double-blind, randomized Phase 2 trial evaluating the efficacy of collagenase clostridium histolyticum, CCH, in canines with benign subcutaneous lipomas. Lipomas are encapsulated deposits of fat often detected as bulges under the skin. The trial did not meet its primary endpoint of a statistically significant post-treatment difference in the mean percent change in lipoma volume by CT scan; however, in the responder analysis there was a statistically significant reduction in lipoma surface area among dogs treated with CCH. The company said, "We are disappointed that the study did not meet its primary endpoint but are pleased that we achieved statistical significance in a responder analysis of those dogs who had a 50% decrease in lipoma surface area as measured by caliper, which is a standard method for measuring a subcutaneous lipoma. We are also encouraged to see a high satisfaction rating from the owners of pets who received CCH and hope to be able to offer them this minimally-invasive treatment." BioSpecifics' strategic partner Auxilium Pharmaceuticals (AUXL) has the option to exclusively license development and marketing rights to the canine lipoma indication, which would trigger an opt-in payment and potential future milestone and royalty payments from Auxilium. BioSpecifics expects to submit a final study report to Auxilium in the first quarter of 2014, which will trigger the 120 day opt-in period. If Auxilium does not opt-in, then the rights will revert back to BioSpecifics. BioSpecifics plans to report top-line results from the Phase 2 human lipoma trial in January 2014.
News For BSTC;AUXL From The Last 14 Days
Check below for free stories on BSTC;AUXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
08:16 EDTAUXLAuxilium management to meet with UBS
Subscribe for More Information
April 11, 2014
07:06 EDTAUXLVIVUS announces avanafil clinical data presentation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use